Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JCR’s Izcargo Reels in Conditional Approval in Kuwait
JCR Pharmaceuticals said on October 14 that its Hunter syndrome drug Izcargo (pabinafusp alfa) received conditional marketing approval in Kuwait this month, marking its second regulatory nod outside Japan following approval in the UAE in July. UAE-based Taiba Middle East…
To read the full story
Related Article
- JCR Licenses Izcargo Rights to Italfarmaco in US, Europe, Latin America
October 5, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
BUSINESS
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
- Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…